All In Biotech

Drug Trial Radar · NCT05017116

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

A Single and Repeated Dose Escalation, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Preliminary Pharmacodynamics of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

Last checked: Nov 19, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Aug 9, 2021

Primary completion

Oct 25, 2023

Study completion Oct 25, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, single (Part A) and repeated dose (Part B) escalation, phase I clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary pharmacodynamics (PD) of RBD1016 in subjects with chronic HBV infection.

Conditions

  • Chronic Hepatitis B

Interventions

  • RBD1016Drug

    subcutaneous injection

  • PlaceboDrug

    subcutaneous injection

  • EntecavirDrug

    Take orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs) and serious adverse events (SAEs) within 28 days after treatment (Part A)Time frame: up to 28 days
  2. Adverse events (AEs) and serious adverse events (SAEs) within 28 days after the last treatment(Part B)Time frame: up to 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Hong Kong

    Hong Kong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.